linjc16/ctgov huggingface dataset:
Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Study Overview
=================
Brief Summary
-----------------
Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis serum antibody to T. gondii and T. canis PCR with peripheral blood for T. gondii and T. canis PCR with aqueous humor for T. gondii and T. canis Clinical manifestation of patient with uveitis

Detailed Description
-----------------
Consecutive patients with uveitis are enrolled in Nune Eye Hospital. Serum ELISA IgM,IgG antibody to Toxoplasma gondii IgG antibody to Toxocara canis PCR PCR with serum and aqueous humor to Toxoplasma gondii PCR with serum and aqueous humor to Toxocara canis Clinical characteristics visual acuity intraocular pressure (IOP) location and degree of inflammation other fundus findings were recorded questionnaire environment, occupation pet ownership, exposure to animal history of eating raw liver of animal, raw beef or any other raw flesh of animal.

Official Title
-----------------
Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Conditions
-----------------
Uveitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with uveitis Exclusion Criteria: Patients with history of major ophthalmic surgery within 6 months antiviral, antifungal or antiparasitic therapy within 6 months
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis | proportion of patients with seropositive for Toxoplasma gondii and Toxocara canis among patients | at baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis | Proportion of patient with positive PCR to Toxoplasma gondii and Toxocara canis | at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Toxoplasma gondii, Toxocara canis
Electrophysiological Mechanisms and Inhibitory Cardiac Syncope

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: To evaluate syncope recurrence at follow up in patients with a positive cardio inhibitory response to the head up tilt testing (HUT) evaluation. METHODS: 36 consecutive patients affected by cardio inhibitory syncope to HUT without asystolia (2A type) have been enrolled in this study. These patients have been studied by electrophysiological study (ES). After ES patients have been differently treated (interventional treatment group A, v/s drug therapy group), and followed up during 360 days, to evaluate syncope recurrences.

Official Title
-----------------
ELectrophysiological Mechanisms Underlying the Inhibitory CArdiac Syncope: Therapeutic and Prognostic Implications The ELICA Study

Conditions
-----------------
Syncope Recurrent

Intervention / Treatment
-----------------
* Device: pacemaker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age more than 18, normal heart function, more than 1 syncope event for year. Exclusion Criteria: age inferior 18 years, history of myocardial infarction, heart failure, structural heart disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: electrophysiological testing<br>Patients will receive a pacemaker. | Device: pacemaker<br> <br> |
| No Intervention: control group<br>These subjects will receive cardicor® (beta blockers). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| syncope recurrence |  | 360 days |
Recognition and Management of Early Mobilization in ICUs : Practice Patterns in China

Study Overview
=================
Brief Summary
-----------------
Despite evidence to support early mobilization（EM）for critically ill patients,current status in Chinese ICUs is unknown.Understanding current practice patterns and challenges is essential to inform future research and strategies.

Detailed Description
-----------------
Practice guideline recommend EM in ICU,feasibility, safety and efficacy are confirmed by evidence-based data.However,the prevalence of EM in ICU patients is still low.Moreover,most of the prevalence studies come from developed countries, such as: Australia and New England the United States and Europe. Many ICUs in non-western countries are suffering from a lack of medical resources including health care personnel and medical equipment. A retrospective observational study.To access the implementation of Chinese intensive care units and hospitals to early mobilization.Secondary objectives were to evaluate structure and process parameters of Chinese hospitals that were associated with implementation.

Official Title
-----------------
Recognition and Management of Early Mobilization in ICUs : Practice Patterns in China

Conditions
-----------------
Early Mobilization

Intervention / Treatment
-----------------
* Behavioral: the nurse did early mobilization
* Behavioral: the nurse do not do early mobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Participating ICUs at least six beds ,they could be medical ,surgical or mixed - Exclusion Criteria: pediatric ICUs
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: the nurse did early mobilization<br>the nurses know and do what is the early mobilization in ICU | Behavioral: the nurse did early mobilization<br>* the nurses know and do what is the early mobilization in ICU<br>|
| Experimental: the nurse do not do early mobilization<br>the nurses do not know and do what is the early mobilization in ICU | Behavioral: the nurse do not do early mobilization<br>* the nurses do not know and do what is the early mobilization in ICU<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the implementation rates for early mobility | the application of physical activity within the first 2 to 5 days of critically illness or injury | within the first 2 to 5 days of critically illness or injury |
Evaluation of 3D Imaging Ulcer Camera

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the intra- and inter-rater variability of wound measurements using the 3D camera and to compare with standard measurement methods (2D image method and gel injection). Forty-eight patients with wounds of various sizes are measured by four clinicians. Each wound is measured twice with the 3D camera, once by 2D image method and once by gel injection into wound cavity by two clinicians.

Detailed Description
-----------------
Diabetic foot ulcers constitute an increasing health problem in Denmark concurrent with an ageing population and an increase in diabetes prevalence. Diabetic foot ulcers belong to the most serious and costly complications. Several studies have found that the size and depth of the wound is one of the major etiologic factors for delayed healing. Wound measurement is important in monitoring the healing process of wound and in evaluating the effect of treatment. Three-dimensional methods for measuring wound size have made it possible to evaluate the process of wound healing with respect to all dimensions. The investigators have developed a 3D camera, which is able to measure wound size (2D area, 3D area, perimeter and volume) and to assess wound characteristics. The aim of the study is to evaluate the intra- and inter-rater variability of wound measurements using the 3D camera and to compare with standard measurement methods (2D image method and gel injection). Forty-eight patients with wounds of various sizes are measured by four clinicians. Each wound is measured twice with the 3D camera, once by 2D image method and once by gel injection into wound cavity by two clinicians.

Official Title
-----------------
Evaluation of Three-dimensional Measurements of Wounds Using a Newly Developed 3D Camera

Conditions
-----------------
Diabetes Mellitus, Diabetic Foot Ulcer, Wound, Chronic Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with wounds 18 years or older Exclusion Criteria: Superficial ulcer (less than 5x5 mm with no substantial loss of subcutaneous tissue) Non-compliance (dementia, mental disorders)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound 2D area | Measured by 3D camera and 2D image method | 1 day | 
| Wound 3D area | Measured by 3D camera | 1 day | 
| Wound perimeter | Measured by 3D camera | 1 day | 
| Wound volume | Measured by 3D camera | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic foot ulcer, Measurement, Wound healing, Measurement device, Three-dimensional measurements
Chronic Post Breast Surgery Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn if paravertebral block (PVB) will reduce chronic pain after surgery. Our hypothesis is that chronic pain from breast surgery as a consequence of central sensitization can be prevented by blocking sensory input to the CNS during surgery and the immediate post-operative period.

Official Title
-----------------
A Prospective, Single-blinded, Randomized, Trial Evaluating the Use of Paravertebral Block to Decrease Chronic Post Breast Surgery Pain.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Paravertebral block
* Procedure: Sham injections


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patient who are ≥ 18 and ≤ 80 years of age. Patient with diagnosis of breast cancer. Patient scheduled for modified radical mastectomy or lumpectomy with axillary node dissection Patient scheduled for one of the above listed surgeries with or without sentinel, partial, or complete axillary lymph node dissection Patients scheduled for one of the aforementioned surgeries with or without immediate or delayed reconstruction. Exclusion Criteria: Pre-existing peripheral neuropathy Pre-existing chronic pain Bilateral procedure Previous breast surgery, except biopsy Inability to read, write or speak English. Allergy to amide local anesthetics Contraindications to paravertebral nerve block including, but not limited to severe scoliosis of the spine, skin lesion overlying the block area, abnormal coagulation studies (some of these may not be known until after informed consent is obtained) Pregnancy Emergency surgery Previous recipients of peripheral nerve block. Medical professional whose experience includes caring for patients who have had peripheral nerve blocks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Block<br> | Procedure: Paravertebral block<br>* 3ml 1% Ropivacaine at each level T1 - T5<br>|
| Sham Comparator: Sham injection<br>Skin injections with Normal Saline | Procedure: Sham injections<br>* Sham injections with Normal Saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To obtain practical experience and information with which to develop a larger, more definitive study, particularly with regard to distributions of VAS responses at 3 months, patient compliance, and achievable accrual rate. |  | 3 months |
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Study Overview
=================
Brief Summary
-----------------
Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe allergic reaction happens.

Detailed Description
-----------------
As a compound traditional Chinese medicine, Tanreqing Injection was approved by China Food and Drug Administration(CFDA) in 2003, and widely used respiratory disease, such as biofilm related upper respiratory infections, pneumonia and bronchitis. During its 11 years marketing in China, there was hardly any serious adverse drug reactions except for a few cases reported as severe allergic reaction. In this study, clinical pharmacists in selected hospitals will not only record the clinical use and the adverse drug reactions/ adverse drug events of this injection, but also try to figure out why drug-induced severe allergic reaction happens through a nested case-control study. This real world study for Tanreqing Injection with 30400 patients will be conducted from January.2014 to June.2016.

Official Title
-----------------
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Conditions
-----------------
Adverse Drug Reaction, Drug Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who use the Tanreqing Injection in selected hospitals in China, including inpatient and outpatient. Outpatients will be only in some hospitals which can get the patients' complete information. Exclusion Criteria: Patients who are less than 24 months.

Ages Eligible for Study
-----------------
Minimum Age: 24 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tanreqing<br>Inpatient using the Tanreqing Injection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reaction of Tanreqing Injection |  | 30 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcomes of the patients who experienced an adverse drug reaction of Tanreqing Injection | Outcomes including cure, improved, null, or death. | 30 months | 
| Administration of Tanreqing Injection in real world |  | 30 months | 
| Population characteristics of the adverse drug reaction of Tanreqing Injection |  | 30 months | 
| Off-lable use of Tanreqing Injection |  | 30 months | 
| Drug combination of Tanreqing Injection in real world |  | 30 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Traditional Chinese Medicine Injection
A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck

Study Overview
=================
Brief Summary
-----------------
This study is a phase II trial designed to test the feasibility of delivering IMRT to head and neck cancer patients with tumours arising in the midline (oropharynx and hypopharynx), and to assess possible improvement in reducing the incidence of xerostomia with bilateral superficial lobe parotid sparing IMRT.

Official Title
-----------------
A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck

Conditions
-----------------
Oropharyngeal Squamous Cell Cancer, Hypopharyngeal Squamous Cell Cancer

Intervention / Treatment
-----------------
* Radiation: Intensity modulated radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed locally advanced HNSCC arising from the oropharynx or hypopharynx with high risk of bilateral parapharyngeal space involvement Exclusion Criteria: Patients <18 years old or with a previous malignancy other than non-melanomatous skin cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| oropharyngeal and hypopharyngeal HNSCC<br>Intensity Modulated Radiotherapy HPV positive and HPV negative | Radiation: Intensity modulated radiotherapy<br>* Bilateral superficial lobe parotid sparing intensity modulated radiotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients reporting grade 2 or more xerostomia using subjective measure on the LENTSOMA late toxicity scoring scale one year after treatment. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute radiation toxicity |  | 0-3 months | 
| Late radiation toxicity |  | 3-24 months | 
| Survival outcomes for entire cohort and according to HPV status where available : Local control, Loco regional control, Loco-regional progression-free survival (LRPFS), Disease free survival, Overall survival. |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
involvement of bilateral parapharyngeal spaces
Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression.

Detailed Description
-----------------
Neonates are susceptible to septicemia secondary to quantitative and qualitative neutrophilic defects. Granulocyte-colony stimulating factor (G-CSF) stimulates myeloid progenitor cell proliferation and induces selective neutrophil functions.

Official Title
-----------------
In Vivo Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on Neutrophilic Expression of CD11b in Septic Neonates

Conditions
-----------------
Neonatal Sepsis

Intervention / Treatment
-----------------
* Drug: rh-GCSF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newborn infants with postnatal age < 28 day, minimum gestational age of 28 weeks and requiring intensive care with clinical signs consistent with the diagnosis of neonatal sepsis, with or without neutropenia Exclusion Criteria: neonates with congenital malformation, major chromosomal abnormalities, prior use of cytokines or intravenous immunoglobulin, or decreased hemoglobin and/or hematocrit at or below the levels necessitate transfusion

Ages Eligible for Study
-----------------
Maximum Age: 4 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control group<br> | |
| Experimental: G-CSF group<br> | Drug: rh-GCSF<br>* 10 ug/kg/day intravenously for 3 days<br>* Other names: Granulocyte colony stimulating factor,neubogen,filgstrim;|
| No Intervention: Non-GCSF group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | one month |
The Effect of Mashed Potato Composition on Food Intake, Satiety and Blood Glucose

Study Overview
=================
Brief Summary
-----------------
Potato is one of the world's most popular foods and is widely accepted as a staple food. The objective of this study is to determine the effect of consuming instant mashed potatoes with and without fat on glycemic response, subjective appetite and food intake. It is hypothesized that mashed potato with added fat (as it is usually consumed) will result in lower glycaemic response and subjective appetite, and reduced subsequent food intake.

Conditions
-----------------
Obesity, Overweight, Diabetes, Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: Dietary treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Healthy men with a body mass index (kg/m2) of 20-24.9 Exclusion Criteria: •smocking, medication, breakfast skipping, restrained eating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mashed Potatoes (as produced)<br> | Other: Dietary treatment<br> <br> |
| Experimental: Mashed Potatoes (with no added butter during production)<br> | Other: Dietary treatment<br> <br> |
| Experimental: glucose control (50 g)<br> | Other: Dietary treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood glucose |  | 120 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| food intake |  | 120 min |